Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027
Amid the COVID-19 crisis, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the period 2020-2027.
The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR
The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
Select Competitors (Total 41 Featured):
Amid the COVID-19 crisis, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the period 2020-2027.
The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR
The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
Select Competitors (Total 41 Featured):
- Alchem International
- Alkaloids of Australia
- ALZA Corporation
- Baxter International Inc.
- Caleb Pharmaceuticals Inc
- Centroflora-Cms
- Fine Chemicals Corporation
- GlaxoSmithKline Plc
- Myungmoon Pharma Co. Ltd.
- Novartis AG
- Perrigo Co. Plc
- Phytex Australia
Note: Product cover images may vary from those shown
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Current & Future Analysis for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 2: World Historic Review for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 3: World 15-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
- UNITED STATES
- Table 4: USA Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 5: USA Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- CANADA
- Table 6: Canada Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 7: Canada Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- JAPAN
- Table 8: Japan Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 9: Japan Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- CHINA
- Table 10: China Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 11: China Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- EUROPE
- Table 12: Europe Current & Future Analysis for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 13: Europe Historic Review for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 14: Europe 15-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
- FRANCE
- Table 15: France Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 16: France Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- GERMANY
- Table 17: Germany Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 18: Germany Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- ITALY
- Table 19: Italy Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 20: Italy Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- UNITED KINGDOM
- Table 21: UK Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 22: UK Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- REST OF EUROPE
- Table 23: Rest of Europe Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 24: Rest of Europe Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- ASIA-PACIFIC
- Table 25: Asia-Pacific Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 26: Asia-Pacific Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- REST OF WORLD
- Table 27: Rest of World Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 28: Rest of World Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Total Companies Profiled: 41
Note: Product cover images may vary from those shown